Radiopharmaceutical company Nusano and Ariceum Therapeutics have signed a multi-isotope supply agreement to support Ariceum’s novel radiotherapeutic pipeline.
The agreement will give the Berlin-based Ariceum access to Nusano-produced radioisotopes, including actinium-225 (Ac-225) and lutetium-177.
Nusano, which opened a new 190,000-sq-ft radioisotope production facility in West Valley City, UT, in August, has a production platform capable of simultaneously manufacturing up to 12 different radioisotopes.
According to Ariceum, reliable access to Ac-225 under the agreement will bolster the clinical-stage oncology firm’s ability to advance its Ac-225 SSO110 radiotherapeutic, a novel antagonist of the somatostatin type 2 receptor.
Ac-225 SSO110 is currently being studied in the SANTANA-225 phase I/II trial as the first maintenance radiotherapy for extensive-stage small cell lung cancer (ES-SCLC) and Merkel cell carcinoma. Ac-225 SSO110 has received investigational new drug clearance and Orphan Drug Designation from the U.S. Food and Drug Administration.
Ariceum is also developing ATT001, a novel radiolabeled iodine-123 PARP inhibitor for aggressive solid tumors.
